GERN - 3 Things In Biotech August 2: Japanese Drug Makers Rise And Fall
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Otsuka failure portends termination of an important AML study
Company: Otsuka (OTCPK:OTSKF)
Therapy: Guadecitabine
Disease: Acute myeloid leukemia (AML); click here to learn more about this disease space!
News: Otsuka announced top-line findings from their pivotal ASTRAL-1 study, which is assessing the hypomethylating agent guadecitabine in patients with newly diagnosed AML who are not candidates for aggressive therapy. The study has failed